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Abstract
Background: Co-infection with hepatitis B virus (HBV) is highly prevalent in people living with HIV in Sub-Saharan Africa.
Screening for HBV surface antigen (HBsAg) before initiation of combination antiretroviral therapy (cART) is recommended.
However, it is not part of diagnostic routines in HIV programs in many resource-limited countries although patients could
benefit from optimized antiretroviral therapy covering both infections. Screening could be facilitated by rapid diagnostic
tests for HBsAg. Operating experience with these point of care devices in HIV-positive patients in Sub-Saharan Africa is
largely lacking. We determined the prevalence of HBV and Hepatitis C virus (HCV) infection as well as the diagnostic
accuracy of the rapid test device Determine HBsAg in an HIV cohort in rural Tanzania.
Methods: Prospectively collected blood samples from adult, HIV-1 positive and antiretroviral treatment-naı¨ve patients in the
Kilombero and Ulanga antiretroviral cohort (KIULARCO) in rural Tanzania were analyzed at the point of care with Determine
HBsAg, a reference HBsAg EIA and an anti-HCV EIA.
Results: Samples of 272 patients were included. Median age was 38 years (interquartile range [IQR] 32–47), 169/272 (63%)
subjects were females and median CD4+ count was 250 cells/mL (IQR 97–439). HBsAg was detected in 25/272 (9.2%, 95%
confidence interval [CI] 6.2–13.0%) subjects. Of these, 7/25 (28%) were positive for HBeAg. Sensitivity of Determine HBsAg
was rated at 96% (95% CI 82.8–99.6%) and specificity at 100% (95% CI, 98.9–100%). Antibodies to HCV (anti-HCV) were
found in 10/272 (3.7%, 95% CI 2.0–6.4%) of patients.
Conclusion: This study reports a high prevalence of HBV in HIV-positive patients in a rural Tanzanian setting. The rapid
diagnostic test Determine HBsAg is an accurate assay for screening for HBsAg in HIV-1 infected patients at the point of care
and may further help to guide cART in Sub-Saharan Africa.
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Introduction
Combination antiretroviral therapy (cART) has drastically
reduced morbidity and mortality of HIV/AIDS in industrialized
countries and recently also in resource-limited settings, including
Sub-Saharan Africa (SSA) [1,2]. Still, certain co-infections and -
morbidities such as liver disease due to viral hepatitis B and C
infection cause considerable morbidity and mortality: Data from
the D:A:D cohort demonstrated liver-related complications to be
the leading cause of non-AIDS related deaths of patients under
cART in Europe, the USA and Australia in 2006 [3]. In the
MACS cohort in the USA, the risk of liver-associated death was
almost 10-fold increased in HIV-positive patients who had
detectable hepatitis B surface antigen (HBsAg) [4].
Epidemiological data collected in rural and urban areas in
various parts of Africa strongly indicate that rates of hepatitis B co-
infection are higher in SSA than in Western Europe or the USA
[5,6,7]. Due to differences in disease epidemiology e.g. the age at
infection with HIV and HBV, the clinical consequences of co-
infection with the hepatitis B virus (HBV) in Africa are presumably
distinct from those found in industrialized countries [5]. Yet to
date, liver-related outcomes in co-infected patients in SSA have
only been assessed to a very limited, cross-sectional extent [8].
Nevertheless, due to a better prognosis of HIV-infection after the
introduction of cART programs in SSA, an increase of patients
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suffering from complications of chronic viral hepatitis B, such as
liver cirrhosis and hepatocellular carcinoma, could result if
concurrent treatment of HBV is not addressed.
Lamivudine, emtricitabine and tenofovir are nucleoside/2tide
reverse transcriptase inhibitors included in standard cART
regimens in Tanzania and other countries in SSA. In addition
to their suppressive effects against HIV, these drugs feature
excellent antiviral activity against HBV [9]. In clinical practice,
appropriate use of these agents in HIV/HBV co-infected patients
results in a halt or even regression of liver cirrhosis, improvement
of biological markers of disease activity and a reduction of
emergence of antiviral resistance of HBV [9,10,11]. The World
Health Organization (WHO) guidelines on antiretroviral therapy
of HIV [12] recommend screening for HBV by means of HBsAg
testing and the inclusion of two dually-active drugs in the
antiretroviral treatment combination of co-infected patients. So
far, routine screening for HBsAg is not included in the majority of
national HIV programs in SSA. One reason for this might be that
standard testing strategies rely on enzyme immuno assays (EIA),
which require a critical and costly amount of infrastructure and
human resources not available outside of urban centers. There-
fore, the implementation of a viable screening strategy to identify
co-infected patients is crucial as an effective intervention, i.e.
cART with dually active components is already in place.
Rapid diagnostic testing (RDT) has successfully facilitated
widespread screening for HIV even in rural Africa. Several point
of care (POC) products for the detection of HBsAg are currently
available but their take-up has been limited so far. The practical
evaluation of these RDT devices in HIV-positive patients in an
African peripheral setting is key in order to study the utility of
including them in diagnostic routines. In this study, we pro-
spectively assessed the diagnostic accuracy and feasibility of
a scalable product locally in a large HIV outpatient clinic in rural
Tanzania.
Materials and Methods
Patient Recruitment, Data Acquisition and Ethics
Statement
Between November 2011 and June 2012, female and male,
adult ($18 years), antiretroviral-naı¨ve, HIV-1 infected patients
consecutively attending the Chronic Disease Clinic of the St.
Francis Referral Hospital in Ifakara, Kilombero district,
Tanzania, were prospectively offered enrollment into this study.
Care at the facility was provided according to the guidelines of
the national AIDS control program (NACP) [13]. Childhood
vaccination for hepatitis B in this region has been introduced
after the year 2002.
Patient data was retrieved from the electronic patient database
of the Kilombero and Ulanga antiretroviral cohort (KIULARCO)
[14]. All subjects included were given oral and written information
and signed an informed consent form. Ethical approval was
granted by the ethical committee of the Ifakara Health Institute
(IHI-IRB Clearence #21/2011) and the Medical Research
coordination Committee of the National Institute of Medical
Research of Tanzania (NIMR/HQ/R.8a/Vol.IX/620-Amend-
ment 01).
Plasma Sample Preparation
Following inclusion into the study, 8 mL of blood were
withdrawn into vacutainers containing ethylenediaminetetraacetic
acid (EDTA). After completion of CD4+ cell counts and the index
test (Determine HBsAg) on whole blood, samples were centrifuged
for 10 min at 20006g. Alanine aminotransferase (ALT) and
creatinine levels were determined, the plasma transferred into
freezer vials and stored at 280uC for later serological analysis.
Serological Assays
All samples were tested both with the index lateral flow assay
Determine HBsAg (Alere Inc., Massachusetts, USA) and the
reference enzyme immunoassay Murex HBsAg 3.0 (Abbott
Diagnostics, Wiesbaden, Germany). Initial reactivity in the
reference assay was confirmed using the Murex HBsAg confir-
matory 3.0 neutralization assay. HCV antibodies were screened
using Murex anti-HCV 4.0 and HBeAg/anti-HBeAg using
DiaSorin ETI-EBK plus and ETI-AB-EBK plus, respectively.
All analyses have been performed on samples obtained from one
blood draw per subject. For the evaluation of Determine HBsAg,
one index assay was conducted using 50 mL of whole, fresh EDTA
blood, followed by a repeat index test using 50 mL of stored
plasma of the identical aliquot utilized for the reference assay.
Both Determine assays were performed by technicians blinded to
the results of the reference test and read by two independent
observers (the first being FF or RN, the second being a laboratory
technician). In case of discordant readings, the result recorded by
the first, i.e. higher qualified observer was used for analysis. Invalid
rapid assay results (i.e. non-appearance of control band) un-
derwent repeated testing once with the same sample. The
distributors indicate sensitivity and specificity of .99.5% and
.99.5% for the reference Murex HBsAg and .95.5% and
.99.95% for Determine HBsAg, respectively. All EIAs were
performed by FF or RN in the laboratory of IHI in Ifakara
according to manufacturer’s instructions. EIA results were
analyzed using automated routines in Excel (Microsoft Inc.,
Redmond, USA). All test kits used in this study were purchased on
the open market.
CD4+ cell counting was performed using a CyFlow Counter
(Partec GmbH, Mu¨nster, Germany) and analysis of ALT and
creatinine with Vitrous DTSC II (Ortho-Clinical Diagnostics, Inc.,
Raritan, NJ).
Statistical Analysis
SAMPLES positive for HBsAg were defined by positive
reactivity in the Murex reference test followed by confirmation
with the Murex neutralization assay. Prevalence of HBsAg and
anti-HCV was defined as count of samples positive divided by
total count of samples tested. We calculated sensitivity,
specificity, negative and positive predictive values out of a 262
cross table using standard definitions [15]. Continuous variables
are expressed as median (interquartile range) and frequencies for
categorical variables. P-values of comparisons of continuous
variables are derived from the Mann-Whitney-U test and from
the x2-test for categorical variables. Confidence intervals for
proportions were calculated according to Jeffrey’s method. Inter-
rater agreement is reported as Cohen’s kappa coefficient.
For the study of diagnostic accuracy, a sample size of 270 was
calculated for a minimal acceptable sensitivity for Determine of
0.9, an estimated prevalence rate of 0.15, a statistical power of 0.8,
and an alpha level of 0.05 [16]. To determine an estimated
prevalence of disease of 15% with a precision of 0.05, a minimal
sample size of 196 was ascertained. All statistical analyses were
performed using Stata 11.2 (StataCorp, Texas, USA). This study
has been designed and published according to the requirements of
the STARD statement for reporting of studies of diagnostic
accuracy [17].
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Results
Patients Characteristics
During 8 months of enrollment, 279 adult eligible patients were
offered to participate in the study as shown in the study profile in
Figure 1. Characteristics of 272/279 (97.5%) consenting patients
are presented in Table 1. The median age at enrollment was 38
years (interquartile range, IQR 32–47) and 169/272 (63%) of
subjects were females. Patients with detectable HBsAg were
significantly more likely to be male and had an elevated
distribution of ALT levels (median 42 U/l, IQR 30–75 vs.
32 U/l, IQR 23–45; p = 0.006) than patients without HBsAg.
Seroprevalence of Viral Hepatitis in Treatment Naı¨ve HIV-
positive Patients
HBsAg was detected in 25 of 272 (9.2%, 95% confidence
interval [CI] 6.2–13.0%) subjects. Of these, 7/25 (28%, 95% CI
13.5–47.2%) were positive for HBeAg and 18/25 (72%, 95% CI
52.7–86.5%) positive for anti-HBeAg. There was no significant
difference in ALT levels between HBsAg+/HBeAg+ (41 U/l, IQR
25–80, n= 7) and HBsAg+/HBeAg- (44 U/l, IQR 32–75, n= 28;
p = 0.71) patients. Antibodies to HCV (anti-HCV) were found in
10/272 (3.7%, 95% CI 2.0–6.4%) of patients and 1/272 (0.36%,
95% CI 0.04–1.7%) had serological evidence of both HBsAg and
anti-HCV.
Assay Performance of Determine HBsAg Rapid Test on
Whole Blood and Plasma
All 272 samples were tested both with the index and the
reference test using samples of the same venipuncture. Median
time to reference and index analysis of the frozen plasma samples
was 25 days (IQR 8–35). All samples showed a conclusive result in
Determine HBsAg upon first time execution of the assay. The
performance of Determine HBsAg is shown in Table 2. Sensitivity
and specificity were 96% (95% CI 82.8–99.6%) and 100% (95%
CI 98.9–100%) respectively, with identical results yielded from
sampling fresh blood and frozen/stored plasma. Inter-rater
agreement (k=0.97, 95% CI 0.93–1) of the two independent
readings of the rapid test was excellent with 1/272 (0.4%) result
line having been rated disconcordantly due to a weak intensity
coloration.
Discussion
The main findings of this study on 272 HIV-infected patients in
a rural Tanzanian setting were a high prevalence of co-infection
with viral hepatitis B and that a rapid diagnostic test for HBsAg is
accurate and precise for screening for HBsAg in our setting.
According to patients’ characteristics, the study population was
representative for HIV-infected patients presenting for care in SSA
[18].
Figure 1. Enrollment and outcome. Study profile of the evaluation of Determine HBsAg against a reference HBsAg enzyme immuno assay.
doi:10.1371/journal.pone.0058468.g001
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The reported prevalence of detectable HBsAg of 9.2% in our
study in HIV-positive patients in Ifakara lies within the range
reported from previous studies in the same area [19] and other
African settings [5]. It is significantly below the 17.3% found in an
HIV outpatient clinic in Dar es Salaam, the urban hub of
Tanzania [20]. The same tendency is observed when comparing
the prevalence of anti-HCV antibodies of 18.1% in the urban
setting, which is almost five-fold higher than the one we found.
This marked variance indicates a difference in the presence and/
or modification of risk factors for acquisition of viral hepatitis
between rural and urban settings. Differences between these two
settings have been reported in SSA before [5,21] but there is no
clear trend in which setting the odds of being infected with viral
hepatitis B are higher.
A positive HBsAg status was associated with moderately
increased ALT levels, which is to be expected due to the
hepatic inflammatory state in patients with active replication of
HBV. Of the patients with detectable HBsAg, 28% showed
HBeAg positivity. A positive HBeAg status is associated with
increased HBV DNA levels [7], thus being a surrogate marker
of high level HBV replication. During HBV infection, HBeAg
follows the appearance of HBsAg. In turn, during recovery,
HBeAg clearance and seroconversion to anti-HBe precede the
loss of HBsAg and detection of anti-HBsAg. Therefore it is
likely that almost three quarters of our patients with detectable
HBsAg were transitioning from a high replicative state to a low
replicative state, with lower risk of progressive liver disease and
further transmission.
This is one of the first studies prospectively evaluating a rapid
test for HBsAg in HIV-infected patients entirely at the point of
care in an African peripheral health institution. We chose
Determine HBsAg for its low waste production, undemanding
storage requirements and most importantly for its preexisting
supply chains, as Determine HIV rapid tests are already part of the
routine HIV testing algorithm in Tanzania [22] and many other
countries. Also, the assay’s procedures and interpretation are
identical with the model used for the diagnosis of HIV; this has the
benefit of cutting down efforts and expenses in training staff for
appropriate handling of the test in case of a large-scale
deployment. Studies performed in Ghana [23] and Madagascar
[24] further indicated that it can be focused on such practical
factors, as differences in diagnostic accuracies between different
products for the detection of HBsAg are marginal. Additionally,
a recent meta-analysis [25] on Determine HBsAg test character-
istics in HIV-negative subjects showed excellent sensitivity and
specificity of 98.2% and 99.9%, respectively.
The few previous studies evaluating this assay in HIV-infected
patients did not report encouraging findings but had limitations,
Table 1. Characteristics of the study population.
HBsAg negative HBsAg positive Total
n=247 (90.8%) n=25 (9.2%) (n=272) p-value
Gender (male) 88 (35.6%) 15 (60%) 103 (37%) 0.017
Age (y) 38 (32–48) 42 (38–56) 38 (32–47) 0.18
WHO Stage I 153 (61.9%) 12 (48%) 165 (60.6%)
II 51 (20.6%) 6 (24%) 57 (20.9%)
III 32 (12.9%) 6 (24%) 38 (13.9%)
IV 11 (4.4%) 1 (4%) 12 (4.4%) 0.417
CD4+ Count (/mL) 260 (99–441) 130 (76–349) 250 (97–439) 0.25
ALT (U/l) 32 (23–45) 42 (30–75) 32 (23–46) 0.006
Creatinine (mmol/L) 73 (58–86) 73 (50–93) 73 (58–86) 0.81
Anti-HCV (positive) 9 (3.6%) 1 (4%) 10 (3.7%) 0.92
HBeAg (positive) not tested 7 (28%) not tested –
Anti-HBeAg (positive) not tested 18 (72%) not tested –
Abbreviations: ALT, alanine aminotransferase; ARV, antiretroviral; HBe-Ag, Hepatitis B envelope antigen; HBsAg, Hepatitis B surface antigen; HCV, Hepatitis C virus; y,
years.
Data are presented as median (interquartile range) for continuous variables and as count (column percentage) for categorical variables. P values hypothesis testing
between HBsAg positive and HBsAg negative are derived from Mann-Whitney U test for continuous and x2-test for categorical variables.
doi:10.1371/journal.pone.0058468.t001
Table 2. Test characteristics of Determine HBsAg determined in comparison with a reference test in adult and antiretroviral-naı¨ve
HIV-1 positive patients in Ifakara, Tanzania.
TP FP TN FN Sensitivity Specificity NPV PPV
Inter-rater
Agreement
N n n n % (95% CI) % (95% CI) % (95% CI) % (95% CI) k (95% CI)
24 0 247 1 96 (82.8–99.6) 100 (98.9–100) 99.5 (98.1–99.9) 100 (90.1–100) 0.97 (0.93–1)
Abbreviations: CI, confidence interval; FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; TN, true negative; TP, true
positive. Agreement is measured between two independent readings of Determine HBsAg.
doi:10.1371/journal.pone.0058468.t002
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notably limited sample sizes: In a study in HIV-positive patients in
Kumasi, Ghana, the sensitivity was found to be only 69.3% with
a specificity of 100%. The majority of samples giving a false
negative result using Determine HBsAg had a concentration of
HBsAg below the determined rapid test’s detection limit and
a substantially lower HBV DNA viral load than samples giving
a true positive result. Unfortunately, that study was retrospective
in nature and results could not be linked to individual
characteristics of the patients of whom the samples were originally
obtained. Importantly, no information on treatment status or
cART regimen was available. It can be hypothesized that present
treatment with the dually-active drug lamivudine partly sup-
pressed replication of HBV in a relevant proportion of patients to
the extent that the concentration of HBsAg was below Determine
HBsAg’s detection limit. In order to limit the effect of this possible
interaction in our study, we only included patients with no prior
cART experience. This also realistically depicts the situation
where screening for HBsAg would take place mainly, namely at
the inclusion into care. Two other studies on Determine HBsAg in
HIV patients were consecutively conducted by a research group in
Malawi. In the first study published in 2008 [26], the assay’s
performance was almost random with sensitivity and specificity of
56% and 69% respectively. The authors concluded that operator
errors, poor documentation and assay storage conditions might
have negatively affected the results. A repetition of the study was
reported in 2010 [27] with a sensitivity and specificity of both
100%. Unfortunately, only a fraction of samples negative with the
index assay actually underwent testing with a reference EIA assay
which introduced a verification bias. For that reason, only the
statement made about specificity can be used without precaution.
Additionally, the rapid testing was not conducted in the point of
care setting in Malawi but in a reference laboratory in Great
Britain. Yet, this result alone is a strong argument for quality issues
in the first of the two studies, as specificity rose from 69% to 100%
using the same assay in the identical cohort. It also re-emphasizes
the need to guarantee good standards in the conduct of rapid
testing, as there are pitfalls even with simple devices.
A study by Hoffmann et al. [28] investigated the performance of
Determine HBsAg in HIV-infected, cART-naı¨ve adults attending
primary or antenatal care in urban South Africa. The sensitivity
and specificity were rated at 75% and 100%, respectively. There
was no identifiable reason reported for the only moderate level of
sensitivity. The authors hypothesized that interaction with HIV
infection itself might have affected performance of the assay.
Reviewing the current evidence, it is not clear how sensitivity of
lateral flow assays for HBsAg is affected by the concurrent
presence of HIV and HBV. On one hand, to assume enhanced
sensitivity seems valid, as the assay directly detects a viral protein
that is expressed in higher concentrations in untreated HIV-
positive compared to HIV-negative patients [29]. Serologic testing
based on the demonstration of antibodies against a pathogen (e.g.
anti-HCV) is more likely to be affected in patients with an altered
function of the immune system [30,31]. However, it can be
hypothesized that factors impairing diagnostic performance of
lateral flow rapid tests are associated with HIV infection. For
example, the possible increased presence of blocking antibodies to
HBsAg and immune-complex formation in the context of HIV
infection and associated hypergammaglobulinemia or the prozone
effect at high concentrations of the target antigen could be
responsible for decreased sensitivity.
Our study provides evidence that Determine HBsAg can
provide testing of good quality in HIV patients in rural Africa.
It improved several limitations of previous studies by pro-
spectively including a well characterized population at a relevant
point of time, at which the assay would likely be used if
adopted in routine screening. Additionally, the study was
planned and reported according to accepted standards for
studies of diagnostic accuracy, which some previous reports
failed to achieve. However, there is a relevant degree of
uncertainty about the estimates due to the limited sample size,
of which previous studies also suffered. It is not clear whether
its findings can be interpolated to other settings as previous
evaluation of Determine HBsAg in HIV patients has shown
considerable heterogeneity of sensitivity between studies.
The opportunities for HBsAg rapid testing in SSA are many
[32]: HIV-infected patients chronically co-infected with HBV
treated in programs offering tenofovir/emtricitabine based regi-
mens could benefit from optimized treatment covering both
infections. Even though the long-term impact of this approach on
clinical outcomes could not have been studied in HIV-positive
subjects in SSA so far, a reduction of complications of chronic
hepatitis B and of liver-related mortality has to be expected.
Treatment with dually active drugs is now recommended by the
WHO [12] and other major international HIV treatment
associations [33,34]. It is the standard in more resourceful
countries. The potential of improving treatment is large, as the
treatment facilities and pharmaceuticals are already available in
many settings. Currently, the missing link between this highly
prevalent co-infection and its effective treatment above all are
barriers in diagnosing it.
There are some limitations to be mentioned. Due to the
cross-sectional nature of the study, the prevalence of chronic
HBV infection, as defined by persistence of HBsAg for .6
months could not be established. Nevertheless, a single mea-
surement reflects the actual field conditions prior to the
initiation of cART. Also, we could not fully characterize HBV
infection in our population due to the lack of other virological
markers. Importantly, the number of HBsAg positive subjects
included was lower than anticipated in the sample size
calculation, which lead to a higher than desired level of
imprecision about the estimates, particularly the sensitivity of
Determine HBsAg. However, we quantified and indicated this.
It must be considered that we used anticoagulated venous blood
for the evaluation of Determine HBsAg and thus no direct
conclusion on the performance with capillary blood can be
drawn. The prevalence estimate of HCV was entirely based on
detection of anti-HCV and was not confirmed by HCV RNA-
PCR. This approach is likely to overestimate the true
prevalence of co-infection with HCV as false positive results
due to cross-reactivity in anti-HCV EIA are common in African
samples [35].
This study includes also strengths. Importantly, the study was
conducted prospectively and entirely at the point of care at a large
out-patient clinic in rural Tanzania. The latter aspect is an
essential proof of concept regarding the feasibility of Determine
HBsAg at a rural site in SSA.
In conclusion, the data presented in this study demonstrate that
Determine HBsAg can offer a readily available and affordable
opportunity for accurate screening of viral hepatitis B in HIV
patients before the initiation of antiretroviral treatment in
a resource-limited setting. This provides the basis for a better
quality of care and treatment of cART.
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